Oppenheimer & CO Inc Biogen Inc. Transaction History

Oppenheimer & CO Inc

  • $6.18 Billion
  • Q2 2024

A detailed history of Oppenheimer & CO Inc transactions in Biogen Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 7,576 shares of BIIB stock, worth $1.32 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
7,576
Previous 7,528 0.64%
Holding current value
$1.32 Million
Previous $1.62 Million 8.19%
% of portfolio
0.03%
Previous 0.03%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024
BUY
$190.52 - $236.72 $9,144 - $11,362
48 Added 0.64%
7,576 $1.76 Million
Q1 2024

May 06, 2024
SELL
$212.02 - $267.71 $769,208 - $971,251
-3,628 Reduced 32.52%
7,528 $1.62 Million
Q4 2023

Feb 13, 2024
BUY
$222.59 - $267.94 $618,577 - $744,605
2,779 Added 33.17%
11,156 $2.89 Million
Q3 2023

Nov 07, 2023
SELL
$253.3 - $285.89 $266,724 - $301,042
-1,053 Reduced 11.17%
8,377 $2.15 Million
Q2 2023

Aug 02, 2023
SELL
$275.25 - $318.06 $226,530 - $261,763
-823 Reduced 8.03%
9,430 $2.69 Million
Q1 2023

May 10, 2023
BUY
$256.56 - $292.34 $794,566 - $905,376
3,097 Added 43.28%
10,253 $2.85 Million
Q4 2022

Feb 07, 2023
SELL
$252.44 - $306.72 $105,015 - $127,595
-416 Reduced 5.49%
7,156 $1.98 Million
Q3 2022

Nov 14, 2022
SELL
$194.69 - $268.46 $79,822 - $110,068
-410 Reduced 5.14%
7,572 $2.02 Million
Q2 2022

Aug 08, 2022
SELL
$187.54 - $223.02 $43,321 - $51,517
-231 Reduced 2.81%
7,982 $1.63 Million
Q1 2022

May 12, 2022
BUY
$193.77 - $244.14 $99,210 - $124,999
512 Added 6.65%
8,213 $1.73 Million
Q4 2021

Feb 02, 2022
BUY
$223.92 - $287.77 $84,865 - $109,064
379 Added 5.18%
7,701 $1.85 Million
Q3 2021

Nov 12, 2021
BUY
$282.99 - $369.05 $123,100 - $160,536
435 Added 6.32%
7,322 $2.07 Million
Q2 2021

Aug 03, 2021
SELL
$259.0 - $414.71 $1.17 Million - $1.88 Million
-4,524 Reduced 39.65%
6,887 $2.39 Million
Q1 2021

May 10, 2021
BUY
$242.95 - $284.63 $714,273 - $836,812
2,940 Added 34.71%
11,411 $3.19 Million
Q4 2020

Feb 11, 2021
SELL
$236.26 - $355.63 $313,517 - $471,921
-1,327 Reduced 13.54%
8,471 $2.07 Million
Q3 2020

Nov 13, 2020
SELL
$264.77 - $305.71 $1.05 Million - $1.21 Million
-3,955 Reduced 28.76%
9,798 $2.78 Million
Q2 2020

Aug 11, 2020
BUY
$258.66 - $342.55 $93,117 - $123,318
360 Added 2.69%
13,753 $3.68 Million
Q1 2020

May 08, 2020
BUY
$268.85 - $341.04 $224,489 - $284,768
835 Added 6.65%
13,393 $4.24 Million
Q4 2019

Feb 07, 2020
SELL
$220.06 - $304.07 $40,050 - $55,340
-182 Reduced 1.43%
12,558 $3.73 Million
Q3 2019

Oct 31, 2019
BUY
$217.44 - $243.88 $7,175 - $8,048
33 Added 0.26%
12,740 $2.97 Million
Q2 2019

Aug 09, 2019
BUY
$219.29 - $241.72 $317,093 - $349,527
1,446 Added 12.84%
12,707 $2.97 Million
Q1 2019

Apr 24, 2019
BUY
$216.71 - $338.96 $81,049 - $126,771
374 Added 3.44%
11,261 $2.66 Million
Q4 2018

Jan 29, 2019
SELL
$278.5 - $352.75 $3,620 - $4,585
-13 Reduced 0.12%
10,887 $3.28 Million
Q3 2018

Oct 26, 2018
BUY
$293.51 - $383.83 $453,472 - $593,017
1,545 Added 16.52%
10,900 $3.85 Million
Q2 2018

Aug 10, 2018
SELL
$257.52 - $306.91 $11.8 Million - $14.1 Million
-45,983 Reduced 83.09%
9,355 $2.72 Million
Q1 2018

May 01, 2018
SELL
$260.13 - $367.91 $589,454 - $833,684
-2,266 Reduced 3.93%
55,338 $15.2 Million
Q4 2017

Feb 07, 2018
BUY
$307.64 - $344.58 $340,557 - $381,450
1,107 Added 1.96%
57,604 $18.4 Million
Q3 2017

Nov 09, 2017
BUY
$281.15 - $329.69 $15.9 Million - $18.6 Million
56,497
56,497 $17.7 Million

Others Institutions Holding BIIB

# of Institutions
1,018
Shares Held
128M
Call Options Held
1.22M
Put Options Held
1.4M
View Full List

About BIOGEN INC.

BIIB Quotes by TradingView
  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email